Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2012

01-12-2012 | Letter to the Editor

Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women

Authors: Antonia García-Martín, Rebeca Reyes-García, Manuel Muñoz-Torres

Published in: Endocrine | Issue 3/2012

Login to get access

Excerpt

Routine measurement of parathormone (PTH) has lead to the identification of high PTH levels without hypercalcemia. This situation, which is known as normocalcemic hyperparathyroidism [1], was defined by Wills in 1962 and is established after ruling out the main causes of secondary hyperparathyroidism. There are conflicting data about its bone effects and clinical course. …
Literature
1.
I. Cakir, K. Unluhizarci, F. Tanriverdi, G. Elbuken, Z. Karaca, F. Kelestimur. Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine (2012). [Epub ahead of print]
2.
L. Rejnmark, P. Vestergaard, C. Brot, L. Mosekilde, Increased fracture risk in normocalcemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study. Calcif. Tissue Int. 88, 238–245 (2011)PubMedCrossRef
3.
S.J. Silverberg, E.M. Lewiecki, L. Mosekilde, M. Peacock, M.R. Rubin, Presentation of asymptomatic primary hyperparathyroidism: proceeding of the third international workshop. J. Clin. Endocrinol. Metab. 94, 351–365 (2009)PubMedCrossRef
Metadata
Title
Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women
Authors
Antonia García-Martín
Rebeca Reyes-García
Manuel Muñoz-Torres
Publication date
01-12-2012
Publisher
Springer US
Published in
Endocrine / Issue 3/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9694-z

Other articles of this Issue 3/2012

Endocrine 3/2012 Go to the issue

Letter to the Editor

Differentiating nonthyroidal illness syndrome from central hypothyroidism in the acutely ill hospitalized patient

Research Letter

Serum vitamin D levels are decreased and associated with thyroid volume in female patients with newly onset Graves’ disease

Editorial

The case against aldosterone: not proven

Original Article

Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer

Original Article

Effects of short- and long-duration hypothyroidism on hypothalamic–pituitary–adrenal axis function in rats: In vitro and in situ studies

Review

Glucose control in diabetes: the impact of racial differences on monitoring and outcomes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits